FCGR3A and breast carcinoma: Secondly, the presence of other associated polymorphisms of the FCGR3A gene could affect the comprehensiveness and preciseness of the relationship between FCGR3A-V158F polymorphisms and clinical outcomes in breast cancer patients on trastuzumab-based therapy.